Add BrightSurf on Google Email

When Gleevec is not enough

Researchers discovered a new 'helper' compound, dasatinib, that effectively treats some leukemias by targeting both BCR-ABL and SRC kinases. The findings suggest addressing both pathways is crucial for optimal treatment outcomes.

SourceJackson Laboratory·JournalProceedings of the National Academy of Sciences·DateNov 7, 2006

How lupus T cells lose IL-2

Researchers found that sera from lupus patients contain antibodies that bind to T cells and suppress IL-2 production through CaMKIV. This deficiency in IL-2 contributes to the autoantibody production seen in lupus, highlighting a new understanding of how microenvironment influences defective T cell function.

SourceJCI Journals·JournalJournal of Clinical Investigation·DateApr 1, 2005

Molecular traffic cop directs cellular signals

Researchers have discovered a new inhibitor called hSef, which regulates the Ras/ERK MAP kinase cascade by limiting ERK activity to specific regions of the cell. This discovery provides insights into how cellular signals are localized and controlled within the cell.

SourceCell Press·JournalDevelopmental Cell·DateJul 12, 2004

Salk news: Understanding organ placement

Researchers at the Salk Institute discovered a complex chain of events leading to Notch activation, which is crucial for proper left-right asymmetry. The study used mathematical modeling to pinpoint factors regulating Notch activity, revealing extracellular calcium as a key trigger.

SourceSalk Institute·JournalNature·DateJan 8, 2004